MedTrace Logo

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD1446 to Healthy Volunteers

NCT00803855 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2009-05-15

No results posted yet for this study

Summary

The primary purpose of this study is to assess the safety and tolerability of AZD1446 following single dose administration.

Conditions

  • Healthy

Interventions

DRUG

AZD1446

oral, single dose

Sponsors & Collaborators

Principal Investigators

  • Didier Meulien, MD, PhD, MSD · AstraZeneca Södertälje

  • Ingemar Bylesjö, MD, PhD · AstraZeneca CPU Huddinge

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00803855 on ClinicalTrials.gov